Cite
HARVARD Citation
Babiker, H. et al. (n.d.). 74PPhase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of oncology. p. . [Online].